Match!
Gareth Pryce
Queen Mary University of London
ImmunologyExperimental autoimmune encephalomyelitisMultiple sclerosisMedicineBiology
116Publications
40H-index
5,310Citations
What is this?
Publications 121
Newest
#1David Baker (QMUL: Queen Mary University of London)H-Index: 156
#2Liaqat Ali (QMUL: Queen Mary University of London)
Last. Lawrence Samkoff (URMC: University of Rochester Medical Center)H-Index: 11
view all 12 authors...
Alemtuzumab was designed to reduce the immunogenicity of the parent, CD52-specific, rat immunoglobulin. Although originally marketed for use in cancer (Mabcampath®), alemtuzumab is currently licensed and formulated for the treatment of relapsing multiple sclerosis (Lemtrada®). Likely, due to its history as the first humanized antibody, the potential of immunogenicity of the molecule has been considered inconsequential, and anti-drug anti-drug antibodies (ADA) responses were similarly reported as...
Source
#1David Baker (QMUL: Queen Mary University of London)H-Index: 156
#2Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
Last. Gavin Giovannoni (QMUL: Queen Mary University of London)H-Index: 75
view all 5 authors...
Source
#1David Baker (QMUL: Queen Mary University of London)H-Index: 156
#2Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
Last. Klaus SchmiererH-Index: 31
view all 5 authors...
Objective: Ocrelizumab inhibits relapsing multiple sclerosis when administered every six months. Based on potential similar memory B cell depletion mechanisms with cladribine and alemtuzumab, we hypothesised that CD20-depletion of B cells by ocrelizumab may exhibit a duration of response exceeding the current licenced treatment interval. Methods: Internet-located information from regulatory submissions and meeting reports relating to the unpublished open-label, phase II ocrelizumab extension tri...
Source
#1Gareth PryceH-Index: 40
#2David BakerH-Index: 156
There are numerous historical reports that people with multiple sclerosis (MS) have for many years been self-medicating with illegally obtained street cannabis or, more recently, medicinal cannabis in the countries where this is available to alleviate the symptoms associated with MS. These anecdotal reports have been confirmed by data from animal models of MS and more recently clinical trials on the ability of cannabinoids to alleviate limb spasticity, which is a common feature of progressive MS...
Source
#1David Baker (QMUL: Queen Mary University of London)H-Index: 156
#2Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
Last. Klaus Schmierer (QMUL: Queen Mary University of London)H-Index: 31
view all 4 authors...
Abstract Oral cladribine is a novel treatment for relapsing multiple sclerosis (MS). This appears to be a semi-selective immune-reconstitution therapy that induces long-term therapy from short treatment cycles. It has a relatively good safety profile that currently does not require extensive monitoring associated with some continuous immunosuppressive and relatively non-selective immune reconstitution therapies. The efficacy and safety of cladribine relates to its particular physicochemical prop...
1 CitationsSource
#1David Baker (QMUL: Queen Mary University of London)H-Index: 156
#2Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
Last. Klaus Schmierer (QMUL: Queen Mary University of London)H-Index: 31
view all 5 authors...
Although many suspected autoimmune diseases are thought to be T cell-mediated, the response to therapy indicates that depletion of B cells consistently inhibits disease activity. In multiple sclerosis, it appears that disease suppression is associated with the long-term reduction of memory B cells, which serves as a biomarker for disease activity in many other CD20+ B cell depletion-sensitive, autoimmune diseases. Following B cell depletion, the rapid repopulation by transitional (immature) and ...
7 CitationsSource
#1Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
#2David Baker (QMUL: Queen Mary University of London)H-Index: 156
Abstract Since their discovery, the existence of secreted oligoclonal immunoglobulin in the central nervous system in people with multiple sclerosis has been the subject of scientific investigation and debate over several decades. Although autoantibodies can be detected in some individuals, probably secondary to release of neo-antigens after damage, evidence for a major, primary involvement of damaging antibodies is still relatively lacking. However, it is possible to construct a working hypothe...
5 CitationsSource
#1Svetlana Gushchina (QMUL: Queen Mary University of London)H-Index: 3
#2Gareth Pryce (QMUL: Queen Mary University of London)H-Index: 40
Last. Xuenong Bo (QMUL: Queen Mary University of London)H-Index: 29
view all 8 authors...
3 CitationsSource
#1Nicolas Dubuisson (QMUL: Queen Mary University of London)H-Index: 4
#2David Baker (QMUL: Queen Mary University of London)H-Index: 156
Last. Klaus Schmierer (QMUL: Queen Mary University of London)H-Index: 31
view all 10 authors...
7 CitationsSource
Source
12345678910